Purpose Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and
pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal …

CT-P59, a monoclonal antibody with potent neutralizing activity against severe acute
respiratory syndrome coronavirus 2, may ameliorate symptoms and prevent hospitalization …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread rapidly
worldwide. This study is the first to report the tolerability, safety, pharmacokinetics (PK), and …

SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …

Vaccines and therapeutics are urgently needed for the pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we screen human monoclonal …

Monoclonal antibodies (mAbs) targeting the severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) spike protein have demonstrated clinical efficacy in preventing or treating …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health
threat for which preventive and therapeutic agents are urgently needed. Neutralizing …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes
coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and …

Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …

Prophylactic and therapeutic drugs are urgently needed to combat coronavirus disease
2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV …